News About: Pharm. Affairs
Anticancer drug became the top imported pharmaceutical product
It was observed anticancer drugs took the highest portion in the total amount of pharmaceutical products that are imported to Korea last year.
Conducted by PharmScore, a health care analysis and assessment result, it...
Once-weekly DPP-4 inhibitor, ‘omarigliptin,’ to be launched in the domestic market
A once-weekly DPP-4 inhibitor diabetes treatment will enter the domestic market.
According to the industry concerned on the 21st, MSD Korea has prepared for the domestic launch of a DPP-4 inhibitor using ‘omariglipti...
Is prescription decrease of Twynsta, a leading hypertension treatment, temporary?
Sales of ‘Twynsta(Boehringer Ingelheim, Yuhan Corporation),’ a hypertension treatment which became a KRW 80 billion leading product based on its product and sales power in the fever of complex drugs, have drawn a down...
Health care industry to manipulate the media against reclassification of emergency contraceptive pills
Facing confirmation of reclassification for emergency contraceptive pills, the pharmaceutical industry has started to use the media to create a favorable image for it.
In 2012, the Ministry of Health and Welfare(MOHW...
Will settlement of ceiling price for antismoking treatments will solve drug price conflict among pharmacies?
The health insurance supporting business for antismoking treatments in pharmacies will be entirely revised and enforced today(19th).
The key is that price of the non-benefited drugs is practically removed as smoking ...
Result of pharmaceutical companies’ avoidance in children OTC drug market
“How has the Janssen’s pain reliever, ‘Tylenol,’ kept its position as a large blockbuster for a long time even with numerous controversy?”
“What is the reason why the children OTC drug market, particularly, has been ...
Will Gilead take over the hepatitis C market, too?
Gilead has attracted attention of the industry if it would continue the success of its domestic antivirus treatment even in the hepatitis C treatment market.
Recently, Gilead has actively established a hepatitis C pr...
Dabictrel approval has been withdrawn even without debut
Hanwha Chemical has voluntarily withdrawn the product approval of ‘Dabictrel(etanercept),’ a Enbrel biosimilar.
Thus, a domestic biosimilar which was approved to be commercialized for the third time has now been disa...
It is unlike Baraclude generics will covet the Viread market
Launched with their low-price advantage, generic products of ‘Baraclude(generic name: entecavir),’ a chronic hepatitis B treatment, seem hard to impact on the market owned by ‘Viread(generic name: tenofovir).’
This i...
Will Boehringer Ingelheim’s ‘nintedanib’ become a victim of the risk sharing system?
As Ildong Pharmaceutical’s idiopathic pulmonary fibrosis(IPF) treatment, ‘Pirespa(generic name: pirfenidone)’ has acquired the health insurance application, its follow-up substance, Boehringer Ingelheim’s nintedanib, ...
